Literature DB >> 8576844

Convergence of direct and indirect pharmacodynamic response models.

W J Jusko1, H C Ko, W F Ebling.   

Abstract

Mesh：

Year:  1995        PMID： 8576844     DOI： 10.1007/bf02353781

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN： 0090-466X


× No keyword cloud information.
  6 in total

1.  Second generation model for prednisolone pharmacodynamics in the rat.

Authors:  A I Nichols; F D Boudinot; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1989-04

2.  A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data.

Authors:  D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

3.  Comparison of four basic models of indirect pharmacodynamic responses.

Authors:  N L Dayneka; V Garg; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

4.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects.

Authors:  W J Jusko; H C Ko
Journal:  Clin Pharmacol Ther       Date:  1994-10       Impact factor: 6.875

5.  Inhibition of rat splenocyte proliferation with methylprednisolone: in vivo effect of liposomal formulation.

Authors:  E V Mishina; W J Jusko
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

6.  Understanding pharmacokinetics and pharmacodynamics through computer stimulation: I. The comparative clinical profiles of fentanyl and alfentanil.

Authors:  W F Ebling; E N Lee; D R Stanski
Journal:  Anesthesiology       Date:  1990-04       Impact factor: 7.892
  6 in total
  27 in total

1.  Characterization of pharmacodynamic recession slopes for direct and indirect response models.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1998-08

2.  Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects.

Authors:  Nageshwar R Budha; Andreas Kovar; Bernd Meibohm
Journal:  AAPS J       Date:  2011-10-18       Impact factor: 4.009

Review 3.  Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.

Authors:  Núria Buil-Bruna; José-María López-Picazo; Salvador Martín-Algarra; Iñaki F Trocóniz
Journal:  Oncologist       Date:  2015-12-14

4.  Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonist.

Authors:  Matthew M Hutmacher; Debu Mukherjee; Kenneth G Kowalski; David C Jordan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

5.  Characterization of the dose-dependent time of peak effect in indirect response models.

Authors:  A Majumdar
Journal:  J Pharmacokinet Biopharm       Date:  1998-04

Review 6.  Expanding clinical applications of population pharmacodynamic modelling.

Authors:  C Minto; T Schnider
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

7.  The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide.

Authors:  M Wakelkamp; G Alván; G Paintaud
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

Review 8.  Characteristics of indirect pharmacodynamic models and applications to clinical drug responses.

Authors:  A Sharma; W J Jusko
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

9.  Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.

Authors:  Shinji Yamazaki
Journal:  AAPS J       Date:  2012-12-19       Impact factor: 4.009

10.  Stochastic modeling of systems mapping in pharmacogenomics.

Authors:  Zuoheng Wang; Jiangtao Luo; Guifang Fu; Zhong Wang; Rongling Wu
Journal:  Adv Drug Deliv Rev       Date:  2013-03-22       Impact factor: 15.470
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.